Stockwinners Market Radar for October 08, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:47 EDT Newmont to divest Akyem for up to $1B - Newmont has "announced it will sell its Akyem operation in the Republic of Ghana to Zijin Mining Group Co., Ltd. under a definitive agreement, for cash consideration of up to $1 billion. The sale is part of Newmont's ongoing program to divest non-core assets as the Company makes a strategic shift to focus on its Tier 1 assets. Under the terms of the agreement, Newmont is expected to receive cash consideration of $900 million upon closing. A further $100 million is expected to be received upon the satisfaction of certain conditions. Proceeds from the transaction will support the Company's capital allocation priorities, including strengthening the balance sheet and returning capital to shareholders. The transaction is expected to close in the fourth quarter of 2024, contingent on satisfaction of customary conditions precedent, including regulatory approvals. As a result, the transaction is not expected to have a material impact on Newmont's 2024 outlook and the Company has not adjusted its non-core guidance for the year. Newmont remains committed to Ghana including the investment of $950 million to $1,050 million of development capital in the Ahafo North gold mining project in the Ahafo region of Ghana."

20:11 EDT Cathie Wood's ARK Investment buys 124K shares of Recursion Pharmaceuticals today

19:50 EDT Maxeon Solar Technologies trading halted, news pending

19:50 EDT Virios Therapeutics trading halted, news pending

19:50 EDT Expion360 Inc trading halted, news pending

19:13 EDT Zealand Pharma issued Complete Response Letter for dasiglucagon in CHI - Zealand Pharma A/S announced that the U.S. Food and Drug Administration has issued a Complete Response Letter, or CRL, for Part 1 of the New Drug Application, or NDA, for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism, or CHI, for up to 3 weeks of dosing. The regulatory review of dasiglucagon is being conducted in two parts under the same NDA. Part 1 relates to dosing of up to 3 weeks and Part 2 relates to the use beyond 3 weeks. Supporting the use of dasiglucagon in CHI beyond 3 weeks, the FDA requested additional analyses from existing continuous glucose monitoring datasets from the Phase 3 clinical program. Zealand expects to submit these data by the end of 2024. The CRL is related to the timing of a reinspection at a third-party contract manufacturing facility that was completed in August/September 2024. The third-party manufacturer has not yet received its inspection classification following the reinspection. A prior inspection of the facility had identified deficiencies that did not involve dasiglucagon. These prior deficiencies had been resolved as of this reinspection. The CRL did not state any concerns about the clinical data package or safety of dasiglucagon. "We at Zealand Pharma are acutely aware of the significant unmet medical need for newborns and children with congenital hyperinsulinism who have either no or very limited treatment options today," said David Kendall, M.D., Chief Medical Officer of Zealand Pharma. "We are committed to working with the FDA and our third-party manufacturing partner to bring dasiglucagon to patients living with this devastating disease in the months ahead."

18:34 EDT Apple CFO Maestri sells 59,305 common shares - In a regulatory filing, Apple CFO Luca Maestri disclosed the sale of 59,305 common shares of the company on October 4 at a price of $226.52 per share.

18:08 EDT Novonix, ICoNiChem sign joint collaboration agreement - Novonix (NVX) and ICoNiChem Widnes "announced the signing of a Joint Collaboration Agreement focused on the development of nickel-based cathode active materials. NOVONIX and ICoNiChem have been selected for funding under the 2024 Canada-UK critical minerals call for proposals, which is focused on advancing projects related to critical minerals essential for industries like renewable energy, electric vehicles, and electronics. To support their participation in the project, NOVONIX Battery Technology Solutions Inc., a Canadian division of NOVONIX, is receiving advisory services and up to CAD $127,928 in funding from the National Research Council of Canada Industrial Research Assistance Program, while ICoNiChem is receiving support through Innovate UK. The 2-year project, with a total budget of CAD $515,686 between NOVONIX and ICoNiChem, aims to further improve the sustainability of the NOVONIX all-dry, zero-waste technology by incorporating recycled metal feedstock, such as cobalt and nickel carbonates and oxides, into the process."

17:18 EDT Centrus Energy unit wins award from DoE for HALEU deconversion - Centrus Energy announced that its subsidiary, American Centrifuge Operating, has won an award from the U.S. Department of Energy to support deployment of technology and equipment to deconvert High-Assay, Low-Enriched Uranium from uranium hexafluoride to uranium oxide and/or uranium metal forms, a key step in the nuclear fuel production process. ACO is one of six awardees being announced today for deconversion, with a minimum contract value of $2M and a maximum value for all awardees of $800M. The ultimate dollar amount associated with this award will depend upon what task orders ACO is subsequently issued and their value.

17:10 EDT Pure Storage founder sells $5.1M in common stock - In a regulatory filing, Pure Storage disclosed that its Founder and Chief Visionary Officer John Colgrove sold 100K shares of common stock on October 4th in a total transaction size of $5.1M.

17:09 EDT Build-A-Bear CEO John sells 48,325 common shares - In a regulatory filing, Build-A-Bear president and CEO Sharon Price John disclosed the sale of 48,325 common shares of the company on October 8 at a price of $35.1885 per share.

17:05 EDT Silvercorp Metals renews mining license at Ying Mining District - Silvercorp Metals announced that the SGX Mine permit has been renewed for another 11 years with an increased capacity of 500,000 tonnes per year, based on the information posted on the website of the Mineral Rights Administration of the Department of Natural Resources of Henan Province. The Yuelianggou Mining License containing the SGX and HZG silver-lead-zinc mines, located in the western part of the Ying Mining District, has been renewed until September 24, 2035 with an increase in production capacity to 500,000 tonnes per year. To renew a mining permit, the Company is required to complete a series of studies and reports, including a Mineral Resource estimate to Chinese standards, a mine development plan, a mine reclamation plan, an environment and soil preservation plan, an Environment Impact Study update, and a safety production facility construction design. All these studies are required to be reviewed by independent panels and then filed with government authorities. Subject to a final assessment of historical government investment in the License area which may result in certain payments, the License in paper certificate will be issued to Silvercorp. Currently, the SGX and HZG mines are operating normally and is also working on the mine optimization plan to achieve allowed production capacity of 500,000 tonnes per year.

17:04 EDT General Dynamics awarded $878M Navy contract modification - General Dynamics was awarded a not-to-exceed $878M undefinitized contract action modification to a previously awarded contract for additional material in support of the planned Virginia Class submarines SSN 812 and SSN 813 and in furtherance of the Navy's commitment to the health and stability of the industrial base. Work is expected to be completed by September 2033. FY24 shipbuilding and conversion funds in the amount of $658.5M will be obligated at time of award and will not expire at the end of the current fiscal year. Naval Sea Systems Command is the contracting activity.

16:54 EDT Lottery.com auditors raise 'substantial doubt' about company as 'going concern' - In a letter, Yusufali & Associates, LLC state: "We have audited the accompanying restated consolidated balance sheets of Lottery.com Inc. as of December 31, 2023, and 2022, and the related consolidated statements of operations and comprehensive loss, equity, and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes. In our opinion, except for the effects of the Company having not filed its 2023 and 2022 United States federal and state corporate income tax returns as described in Note 14 of the financial statements, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and 2022, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has stockholder's deficit, net losses, and negative working capital. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

16:31 EDT Granite announces $34M seismic improvement project at OAK - Granite announced the signing of a $34M contract to implement seismic improvements to the Oakland International Airport Perimeter Dike. This critical infrastructure project is designed to protect the airport runway from water intrusion from the adjacent San Francisco Bay. Project funding comes in part from the Federal Aviation Administration and will be included in Granite's third-quarter CAP. The primary objective of this project is to enhance the seismic resilience of 4,200 LF of the OAK perimeter dike by utilizing a cement deep soil mixing construction solution. This technique will strengthen the levee wall soils and mitigate the risk of dike failure in the event of a strong seismic event. Keller North America, Inc, a leading geotechnical specialty subcontractor, performed the CDSM scope. In addition to the 62,295 CY of CDSM scope, other work includes clearing and grubbing, constructing temporary work pads, installing wetlands protections, protecting in-place existing fuel lines, and installing 2,100 CY of additional rip rap revetment and aggregate base surfacing to restore the existing perimeter road. "This project is a strategic win for Granite as we continue to build our portfolio of work with the Port of Oakland," said Brent Fogg, Granite Vice President of Regional Operations. "The technical challenges and restricted access of this project will require meticulous logistical planning to ensure an efficient and safe workflow and zero impact on Airport Operations."

16:25 EDT Cohen & Steers reports preliminary AUM of $91.8B as of September 30 - Cohen & Steers reported preliminary assets under management of $91.8B as of September 30, 2024, an increase of $3.7B from assets under management of $88.1B at August 31, 2024. The increase was due to market appreciation of $2.6B and net inflows of $1.3B, partially offset by distributions of $286M.

16:21 EDT Worthington CEO Andy Rose to retire, Joseph Hayek to succeed - Worthington board of directors announced Joseph Hayek as the company's next president and chief executive officer, or CEO, effective November 1. Hayek, who currently is the company's executive vice president, chief financial and operations officer, will replace Andy Rose who is retiring. Worthington Enterprises board of directors chairman John Blystone, said, "Joe is a proven leader with a deep understanding of the business, Worthington's culture and a demonstrated ability to capitalize on the opportunities ahead. We expect a seamless and effective transition as Joe has earned the respect of the Board, our employees and the investment community, and we look forward to continuing to support him and his leadership team as they drive long-term shareholder value."

16:14 EDT Immucell reports Q3 revenue $6M, one estimate $5.4M - ImmuCell announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30. During the three-,nine- and twelve-month periods ended September 30 annualized production output was approximately 73%, 81% and 77%, respectively, of the company's estimated full capacity of approximately $30M per year. As of September 30 the backlog of orders aggregated approximately $7.3M. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of the first quarter calving season..."We continue to work to achieve FDA approval to commercialize Re-Tain ," commented Michael F. Brigham, President and CEO of ImmuCell. "We plan to provide an update when we have filed our Non-Administrative NADA . We anticipate making this submission later this year, shortly after the inspectional observations at our contract manufacturer are resolved to the satisfaction of the FDA. We have been in discussions with the FDA about an expedited review at that point."

16:13 EDT Myriad Genetics announces five research collaborations to study MRD testing - Myriad Genetics announced a series of ongoing research collaborations to study the use of molecular residual disease, or MRD, testing in breast cancer using Myriad's Precise MRD test. A study to determine whether circulating tumor DNA, or ctDNA, level may predict magnitude of response to pembrolizumab and hormonal therapy in patients with HR-positive inflammatory breast cancer who did not achieve pathological complete response at the time of surgery, led by Bora Lim, at The University of Texas MD Anderson Cancer Center. A study to evaluate whether ctDNA levels correlate with nodal involvement in patients with newly diagnosed HR-positive breast cancer and, if so, how the correspondence may be used to aid in surgical decision making, led by Anna Weiss, at The University of Rochester Medical Center. The multicenter, prospective MONITOR-breast study to determine the association of ctDNA levels to both neoadjuvant and adjuvant therapy in patients with newly diagnosed breast cancer across all subtypes. The study will involve 650 patients and will assess the prognostic potential of ctDNA and the lead time of detecting recurrence earlier ahead of standard-of-care imaging. The multicenter, prospective study JBCRG-C11 to evaluate the maintenance of complete response with trastuzumab deruxtecan in HER2-positive advanced or metastatic breast cancer patients and whether ctDNA can be used to optimally guide therapy, led by Yoichi Naito, of the National Cancer Center Hospital East in Japan. A study in partnership with Aptitude Health to assess ctDNA levels in high-risk patients at diagnosis, during neoadjuvant treatment, and following surgery in community oncology settings.

16:09 EDT Arena Group receives continued listing standard notice from NYSE - The Arena Group Holdings announced that it received a notification on October 2, 2024 from the NYSE American informing the Company that it is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide requiring stockholders' equity of (i) $2.0 million or more if the Company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, (ii) $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and (iii) $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively.

16:07 EDT Insmed presents data from Phase 3 ASPEN study - Insmed presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found HERE. These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston, along with several other presentations from across Insmed's respiratory portfolio. "The positive results from the landmark Phase 3 ASPEN study have generated tremendous excitement among physicians and patients alike, providing hope for a much-needed approved treatment for bronchiectasis," said lead study investigator James Chalmers, Professor and Consultant Respiratory Physician at the School of Medicine, University of Dundee, UK. "It is particularly exciting to see that, consistent with the overall trial analysis, brensocatib 25 mg was able to slow lung function decline as measured by FEV1 for all prespecified subgroups, further underscoring the potential impact this investigational treatment candidate may have on a diverse range of patients if approved." Consistent with positive results for the overall ASPEN population, the annualized rate of pulmonary exacerbations favored brensocatib at both the 10 mg and 25 mg doses over placebo for almost all subgroups. In a separate analysis, least squares mean difference for brensocatib 25 mg demonstrated a reduced decline in post-bronchodilator FEV1 at Week 52 versus placebo for all prespecified subgroups. Results for patients treated with brensocatib 10 mg among subgroups were aligned with the overall trial population results. Insmed plans to file a New Drug Application with the FDA for brensocatib in patients with bronchiectasis in the fourth quarter of 2024. Pending regulatory approvals, Insmed anticipates a U.S. launch for brensocatib in mid-2025 followed by launches in Europe and Japan in the first half of 2026. If approved, brensocatib would be the first approved treatment for patients with bronchiectasis as well as the first approved dipeptidyl peptidase 1 inhibitor-a new mechanism of action with the potential to address a range of neutrophil-mediated diseases.

16:06 EDT Zeta Global to acquire LiveIntent for $250M - Zeta Global announced it has entered into an agreement to acquire LiveIntent. Founded in 2009, LiveIntent is a pioneer in people-based marketing, with proprietary technology powering mobile-centric experiences and first-party identity solutions to identify, unlock, engage, and monetize audiences across channels. "We are excited to welcome LiveIntent to Team Zeta as we continue to build out our position and sharpen our differentiation in AI-powered marketing," said David A. Steinberg, Co-Founder, Chairman, and CEO of Zeta Global. "We have gotten to know the LiveIntent team through our work with them over the past five years and have seen firsthand the benefits of their core assets and experienced the impact of their platform. As more brands view first party data as a corporate asset, seek to make AI actionable, and move towards a single platform that powers more efficient and effective marketing across the customer lifecycle, this acquisition accelerates Zeta's flywheel and positions the combined company to continue to grow faster than the market." Pursuant to the definitive merger agreement, Zeta will purchase LiveIntent for a total consideration of $250 million, subject to customary adjustments, in the form of $77.5 million in cash-on-hand and $172.5 million in common stock at closing. The stock consideration is subject to a lockup and limitations on sale volume following the release. The agreement also provides for a potential earnout of 50% cash and 50% stock tied to significant Adjusted EBITDA growth and sustained margin expansion targets in each of fiscal years 2025, 2026, and 2027. The maximum potential earn-out consideration is $25 million per year for each of the three years. Zeta has also agreed to issue $25 million in Performance Stock Units to the LiveIntent management team tied to certain performance and retention targets for fiscal years 2025, 2026, and 2027. The transaction is expected to close in the fourth quarter of 2024 and is subject to customary closing conditions.

15:26 EDT Universal Studios Florida will be closed on Thursday, October 10 - In a weather update at 2:15 PM, Universal Orlando Resort stated: "Due to Hurricane Milton, Universal Orlando Resort is making the following operational changes for Wednesday, Oct. 9 and Thursday, Oct. 10. On Wednesday, Oct. 9, Universal Studios Florida, Islands of Adventure and Universal CityWalk will be open until 2 p.m. and will be closed on Thursday, Oct. 10. (*Note: Hours of operation are subject to change based on forecast alterations and some attraction and experience availability may be limited on Wednesday as we prepare for an early closure). Universal Volcano Bay will be closed Wednesday, Oct. 9 and Thursday, Oct. 10. Halloween Horror Nights at Universal Studios Florida is canceled for Wednesday, Oct. 9 and Thursday, Oct. 10. Our hotels remain operational as they focus on taking care of our guests. We anticipate a full reopening of our destination, including Halloween Horror Nights, on Friday, Oct. 11 at our normal operating hours pending the outcome of storm impacts." Reference Link

14:59 EDT Immuneering treatment of pancreatic cancer granted FDA orphan status - Immuneering's treatment of pancreatic cancer was granted FDA orphan designation, according to a post to the agency's website. Reference Link

14:39 EDT Hearst and OpenAI announce strategic content partnership - Hearst announced a new content partnership with OpenAI which will integrate Hearst's extensive newspaper and domestic magazine content into OpenAI's products, enhancing the utility and reach of both companies' offerings. As part of the partnership, OpenAI will incorporate content from Hearst's celebrated brands of trusted journalism - including Houston Chronicle, San Francisco Chronicle, Esquire, Cosmopolitan, ELLE, Runner's World, Women's Health and others - into its advanced AI products. This collaboration spans over 20 magazine brands and 40+ newspapers, enriching ChatGPT's 200 million weekly users with a vast array of lifestyle content. From local news to fashion and home design and health, fitness, and automotive insights, users will now experience an even broader and deeper connection to the topics that shape their daily lives. "As generative AI matures, it's critical that journalism created by professional journalists be at the heart of all AI products," said Hearst Newspapers President Jeff Johnson. "This agreement allows the trustworthy and curated content created by Hearst Newspapers' award-winning journalists to be part of OpenAI's products like ChatGPT - creating more timely and relevant results." "Our partnership with OpenAI will help us evolve the future of magazine content," said Hearst Magazines President Debi Chirichella. "This collaboration ensures that our high-quality writing and expertise, cultural and historical context and attribution and credibility are promoted as OpenAI's products evolve."...Investors in OpenAI include Microsoft (MSFT), Thrive Capital, Khosla Ventures, Fidelity Management, Nvidia (NVDA), and SoftBank (SFTBY). Reference Link

14:31 EDT General Motors to build battery cell development center in Michigan - General Motors announced at its Investor Day that it "will be building a battery cell development center at our global tech center in Warren, Michigan."

14:26 EDT States sue TikTok alleging that platform exploits and harms young users - California Attorney General Rob Bonta and New York Attorney General Letitia James co-led a bipartisan coalition of 14 attorneys general in filing separate enforcement actions against TikTok for violations of state consumer protection laws. Filed in Santa Clara County Superior Court, Attorney General Bonta's action alleges that TikTok exploits and harms young users and deceives the public about the social media platform's dangers. The action seeks significant penalties, as well as injunctive and monetary relief, to address TikTok's misconduct. "Our investigation has revealed that TikTok cultivates social media addiction to boost corporate profits. TikTok intentionally targets children because they know kids do not yet have the defenses or capacity to create healthy boundaries around addictive content," said Attorney General Rob Bonta. "When we look at the youth mental health crisis and the revenue machine TikTok has created, fueled by the time and attention of our young people, it's devastatingly obvious: Our children and teens never stood a chance against these social media behemoths. TikTok must be held accountable for the harms it created in taking away the time - and childhoods - of American children." Publicly traded companies in the social media space that compete with TikTok include Meta Platforms (META), Alphabet (GOOGL), Pinterest (PINS), Reddit (RDDT) and Snap (SNAP). Reference Link

13:59 EDT GM says EV losses to peak in 2024, to focus on improving profitability in 2025 - Discussing 2025 at the company's Investor Day, General Motors said it expects performance "will be in a similar range to 2024." "We believe our EV losses peak this year, and we're focused on significantly improving profitability next year. We will exit 2024 with a fixed cost structure that is $2B lower than two years ago. GM and our partner SAIC are taking bold steps to make sure our joint venture in China is profitable and sustainable. In China, you will begin to see evidence of a turnaround yet this year with a significant reduction in dealer inventory and modest improvements in sales and share. A combination of these factors will allow us to continue to generate and return significant cash to shareholders after we reinvest in the business. We expect to reduce our common shares outstanding to less than one billion by early next year. That is down about 600,000,000 shares from our peak."

13:11 EDT United Parks says Orlando, Tampa parks closed Wednesday, Thursday - Following the latest updates on Hurricane Milton, United Parks & Resorts issued this information on each of its Florida parks: "Busch Gardens Tampa is CLOSED on Tuesday, October 8th, Wednesday, October 9th and Thursday, October 10th. Howl-O-Scream is cancelled for Thursday, October 10. Tickets may be used for any remaining Howl-O-Scream event nights; Adventure Island remains running on its seasonal schedule without changes at this time. Please check our social media for updates regarding park opening on Friday, October 11; SeaWorld Orlando remains OPEN on Tuesday, October 8th. We will be CLOSED on Wednesday, October 9th and Thursday, October 10th; Aquatica Orlando remains OPEN on Tuesday, October 8th. We will be CLOSED on Wednesday, October 9th and Thursday, October 10th. All date-intended tickets for closure days have been extended through December 31, 2024 and requires no action to be taken. Discovery Cove remains OPEN on Tuesday, October 8th. We will be CLOSED on Wednesday, October 9th and Thursday, October 10th. Our Named Storm Policy is in effect." Reference Link

12:09 EDT Smartsheet, AWS partner to synchronize data into Amazon Q Business - Today at its annual ENGAGE customer conference, Smartsheet (SMAR) announced it is partnering with AWS (AMZN) to launch a new connector that synchronizes data from Smartsheet into Amazon Q Business, a generative AI-powered assistant that can answer questions, provide summaries, generate content, and securely complete tasks based on data and information in customers' enterprise systems. "The connector will enable Amazon Q Business customers to query their intelligent assistant for information about their projects, programs, and processes managed in Smartsheet, offering a unified search experience across their knowledge base so employees can make data-driven decisions and operate at peak."

12:02 EDT Take-Two's Rockstar says first 'Red Dead Redemption' coming to PC October 29 - Take-Two's Rockstar Games said that 2010 game "Red Dead Redemption" and its "Undead Nightmare" expansion will arrive on PC for the first time October 29. "In collaboration with Double Eleven, this new version adds PC-specific enhancements including native 4K resolution at up to 144hz on compatible hardware, monitor support for both Ultrawide (21:9) and Super Ultrawide (32:9), HDR10 support, and full keyboard and mouse functionality," the company said. "There's also support for NVIDIA DLSS 3.7 and AMD FSR 3.0 upscaling technologies, NVIDIA DLSS Frame Generation, adjustable draw distances, shadow quality settings, and more." Reference Link

12:00 EDT Citizens rises 9.1% - Citizens is up 9.1%, or 41c to $4.93.

12:00 EDT Mytheresa rises 20.7% - Mytheresa is up 20.7%, or $1.40 to $8.16.

12:00 EDT JinkoSolar falls -18.1% - JinkoSolar is down -18.1%, or -$5.92 to $26.85.

11:44 EDT Inno Holdings announces 1-for-10 reverse stock split - Inno Holdings' board of directors approved a reverse stock split of Inno's common stock, no par value, at a ratio of 1-for-10. The Reverse Stock Split is expected to become effective immediately after the close of trading on the Nasdaq Capital Market on October 9, 2024, and Inno's Common Stock is expected to begin trading on the Nasdaq on a split-adjusted basis at the opening of trading on October 10, 2024, under the existing ticker symbol "INHD". The Company filed an amendment to its Certificate of formation on October 8, 2024, to implement the Reverse Stock Split as of the Effective Time. The primary goal of the Reverse Stock Split is to increase the per share market price of the Common Stock to regain compliance with the minimum $1.00 average closing price requirement for continued listing on the Nasdaq.

11:36 EDT Aurigene Oncology announces results of Phase 1 study of DRL-1801 - Aurigene Oncology has announced the Phase 1 results for Ribrecabtagene autoleucel from the SWASTH study - India's first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patients achieved clinical response, with 5/8 having achieved stringent complete response. With respect to safety, there were no high-grade events of Cytokine Release Syndrome or neurotoxicity, in any of the patients. After reviewing the Phase 1 data, the Indian Regulatory Agency i.e., Drugs Controller General of India, has given the nod to commence Phase 2 part of the trial. These results of Phase 1 were presented at the 21st annual meeting of the International Myeloma Society at Rio De Janeiro, Brazil, held recently. Ribrecabtagene autoleucel is an autologous anti-BCMA CAR-T therapy that utilizes a humanized single-domain antibody as the antigen binding domain and lentivirus as a vector. DRL-1801 for the clinical trials is manufactured at the CAR-T GMP manufacturing facility at Aurigene Oncology Limited, Bangalore.

11:25 EDT Innovaro Inc trading resumes

11:06 EDT Boeing announces Q3 total commercial airplane deliveries of 116 - Boeing said it delivered 92 737s, 6 767s, 4 777s and 14 787s in Q3, for a total of 116 commercial airlines. Total defense, space & security program deliveries for Q3 were 34. Year-to-date, Boeing delivered 291 commercial airplanes and made 76 defense, space & security program deliveries.

10:04 EDT Precipio expands Bloodhound MPN panel by adding CALR mutation subtyping - Precipio announces the launch of a new version of its Bloodhound MPN panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network guidelines released in August of this year. This is the only quantitative PCR-based panel of its kind on the market that distinguishes between CALR Type 1 and Type 2 alongside the other genes relevant to the molecular evaluation of MPN.

10:02 EDT Cree LED partners with IDC Componentes, Ilumiled - Cree LED announced the city of Santiago de Queretaro in central Mexico has tapped IDC Componentes and Ilumiled to upgrade all of its downtown lighting-a project that will replace 1600 sodium-based lamps with LED fixtures. Authorized by the state and municipal governments, the upgrade maintains the downtown area's light color and softness while improving the light uniformity and cutting power consumption by more than half over the next five to 10 years.

10:01 EDT PPG, Shaw Industries sign strategic agreement for resinous flooring products - PPG announced that it has signed a strategic agreement with flooring leader Shaw Industries Group to offer the PPG FLOORING line of resinous flooring products. The products will be available to Shaw's customers in the commercial property market via its Patcraft brand. The partnership helps expand the market reach for PPG's products and adds to Shaw's expansive portfolio of flooring and surface solutions.

10:01 EDT Azul rises 18.0% - Azul is up 18.0%, or 57c to $3.77.

10:00 EDT Lufax falls -16.4% - Lufax is down -16.4%, or -65c to $3.32.

09:55 EDT WeightWatchers jumps after adding compounded weight loss drugs - Shares of WeightWatchers are moving higher after the company announced the addition of compounded semaglutide into its offering. "Shortages of GLP-1 medications have plagued the market for more than two years, with patients often unable to find name-brand medications in stock at their local pharmacies. Over the past year, WeightWatchers has called local pharmacies across the country on behalf of members to conduct almost 3 million stock checks for GLP-1 medications and found them in stock just 4.5% of the time. These shortages can result in delays or interruptions of treatment, which negatively impact health outcomes for patients," the company said in a statement. "Given the ongoing shortages of branded medications such as Ozempic and Wegovy, WeightWatchers is committed to ensuring our members still have access to effective alternatives and the support they need to achieve the health outcomes they deserve," the company added. Shares of WeightWatchers are up 9% to 86c in morning trading.

09:48 EDT Lufax falls -16.7% - Lufax is down -16.7%, or -66c to $3.31.

09:47 EDT Aeva Technologies rises 3.6% - Aeva Technologies is up 3.6%, or 12c to $3.57.

09:47 EDT Azul rises 15.4% - Azul is up 15.4%, or 49c to $3.68.

09:40 EDT Neonode appoints Peter Kruk to board of directors - Neonode announced that Peter Kruk has joined the company's Board of Directors as a Class II director. Peter Kruk currently serves as the CEO and as a board member of NCAB Group AB, a Nasdaq Stockholm-listed company and a leading global producer of printed circuit boards.

09:36 EDT Sobr Safe Inc trading resumes

09:34 EDT Bell Media, Warner Bros. Discovery expand partnership in Canada - Bell Media (BCE) has expanded its landmark partnership with Warner Bros. Discovery (WBD) for the Canadian market, extending Crave for multiple years as the exclusive home of HBO and Max content. The expansion of Bell Media's existing licensing agreement with Warner Bros. Discovery, announced in 2023, ensures Crave subscribers have continued access to a vast library of premium content for the foreseeable future. The new agreement also includes a co-production commitment for original Canadian content with global appeal, licensing of Bell Media original content for use on Warner Bros. Discovery platforms outside of Canada, and extended access to French-language content for use on Bell Media platforms. Bell Media and Warner Bros. Discovery also confirmed today that they have settled all matters in their recent dispute regarding Bell Media's suite of Discovery-branded channels. Details regarding changes to Bell Media-owned Discovery channels will be made available in the coming weeks.

09:32 EDT Walmart expands pet care offerings with new service locations, online vet access - Walmart announced key expansions to its core pet care offerings, widening access to in-person and virtual veterinary care, pet prescription delivery, grooming services, and pet food and supplies. Walmart announced the expansion of its Walmart Pet Services centers, planned to open over the next month in the following cities: Cumming, Georgia; Alpharetta, Georgia; Glendale, Arizona; Chandler, Arizona; Mesa, Arizona. In addition, starting October 18, Walmart will officially launch its Walmart+ benefit with Pawp, which was announced earlier this year. This new online pet care service will give Walmart+ members free, 24/7 access to Pawp's team of veterinary professionals with unlimited $0 visits via text or video.

09:30 EDT Container Store adopts limited duration stockholder rights plan - Container Store Group announced that it has adopted a limited duration stockholder rights plan, which is effective immediately and is scheduled to expire on October 7, 2025. The company's board of directors adopted the rights plan in response to the rapid and significant accumulation of the company's common stock by a single stockholder and to protect value for all of the company's stockholders. Under the rights plan, one preferred stock purchase right will be distributed for each share of common stock held by shareholders of record on October 23. The rights will become exercisable if a person or group acquires 20% or more of the company's common stock. In such event, each right will entitle its holder to purchase, at the then-current exercise price, additional shares of the Company's common stock at a 50% discount. Except as provided in the rights plan, the board is entitled to redeem the rights at $0.01 per right. The rights will expire on October 7, subject to the company's right to extend such date, unless earlier redeemed or exchanged by the company or terminated. Under the rights plan, any person who currently owns more than the Triggering Percentage may continue to own its shares of common stock but may not acquire any additional shares without triggering the rights plan. The rights plan does not prevent any action that the board determines to be in the best interest of the company and its stockholders. The dividend distribution to establish the new rights plan will be payable to stockholders of record on October 23. Additional details about the rights plan will be contained in a Form 8-K to be filed by the company with the Securities and Exchange Commission.

09:30 EDT Astellas Pharma, AviadoBio announce license agreement for AVB-101 - AviadoBio and Astellas Pharma announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development for patients with frontotemporal dementia with progranulin mutations. Under the terms of the agreement, Astellas will have the option to receive a worldwide exclusive license for the development and commercialization rights to AVB-101 in FTD-GRN and other potential indications. Astellas will make a $20M equity investment and up to $30M in upfront payments for the option to license AVB-101. AviadoBio is also eligible to receive up to $2.18B in license fees and milestone payments plus royalties if Astellas exercises its option.

09:27 EDT Palladyne AI completes Phase I of Air Logistics Complex contract - Palladyne AI announced that it has completed Phase I of its previously announced multi-million-dollar contract with the Air Logistics Complex at Warner Robins Air Force Base in Georgia. Phase II will continue integration and use case validation of Palladyne IQ software for use in remediation activities including media blasting for complex aircraft components. This is the second year of a contemplated four-year effort valued at $13.8M, the result of Palladyne AI's selection in the highly competitive Strategic Funding Increase program emerging from the Air Force's innovation incubator, AFWERX AFVentures. In Phase II of the contract, Palladyne IQ software will be used in preparation of complex, high-value aircraft components of varying types and sizes via detection, identification, and surface mapping to maintain the correct distance and angle for optimal application of surface preparation materials.

09:20 EDT Container Store adopts limited duration stockholder rights plan - Container Store announced that it has adopted a limited duration stockholder rights plan, which is effective immediately and is scheduled to expire on October 7, 2025. "The Company's Board of Directors adopted the rights plan in response to the rapid and significant accumulation of the Company's common stock by a single stockholder and to protect value for all of the Company's stockholders. The limited-duration rights plan is designed to promote the fair and equal treatment of all stockholders of the Company, ensure that the Board remains in the best position to discharge its fiduciary duties to the Company and its stockholders, guard against any stockholder obtaining undue influence over the Company through open market accumulations and provide all stockholders an opportunity to maximize the value of their investment in the Company. The rights plan is similar to plans adopted by other publicly traded companies. Under the rights plan, one preferred stock purchase right will be distributed for each share of common stock held by shareholders of record on October 23, 2024. The rights will become exercisable if a person or group acquires 20% or more of the Company's common stock (including shares that are synthetically owned pursuant to derivative transactions or ownership of derivative securities). In such event, each right will entitle its holder (other than the person or group triggering the rights plan, whose rights will become void and will not be exercisable) to purchase, at the then-current exercise price, additional shares of the Company's common stock at a 50% discount. Except as provided in the rights plan, the Board is entitled to redeem the rights at $0.01 per right. The rights will expire on October 7, 2025, subject to the Company's right to extend such date, unless earlier redeemed or exchanged by the Company or terminated. Under the rights plan, any person who currently owns more than the Triggering Percentage may continue to own its shares of common stock but may not acquire any additional shares without triggering the rights plan. The rights plan does not prevent any action that the Board determines to be in the best interest of the Company and its stockholders. The dividend distribution to establish the new rights plan will be payable to stockholders of record on October 23," the company stated.

09:15 EDT Crexendo selected by Symbio to launch AdvancedPBX solution - Crexendo announced its partnership with Symbio to launch AdvancedPBX, a cloud based communications solution. This solution is built on Crexendo's NetSapiens platform which recently surpassed 5 million global users and is the third largest, and fastest growing software platform in North America, according to Frost & Sullivan. Crexendo's NetSapiens platform is designed to empower service providers with a fast, scalable, and feature-rich system that can be configured in minutes, not days. Symbio's AdvancedPBX will utilize Crexendo's NetSapiens platform to deliver a suite of communication features, including advanced contact center capabilities and AI-driven smart call transcription. It is provisioned through Telcoinabox's operations and business support systems, streamlining deployment and management resulting in the ability to turn up service in 5 minutes.

09:13 EDT Methes Energies introduces biodegradable bar & chain oil - Methes Energies announced the introduction of their new biodegradable bar & chain oil made with domestically sourced renewable bio-base stocks and branded as b2 biOil "all season" bar & chain oil for use with all chainsaws. It has been estimated that over 20 million gallons of bar & chain oils are lost through application every year as oil is released from the bar after a few revolutions...spraying or adhering to the sawdust all over the work area as virtually 100% of the lubricant ends up in the environment. By switching to a biodegradable bar & chainsaw oil made with American grown base stocks will further help reduce environmental pollution. b2 biOil "all season" bar & chain oil is formulated for use with all makes and models of chainsaws in the harshest weather condition. Made with domestically harvested vegetable oils, the product exhibits excellent flow characteristics and super lubricity even in low temperatures. In addition to the superior performance, the oil remains harmless to humans and the environment, representing an ideal balance between high performance and an environmentally safer solution for the socially responsible end-user/operator.

09:11 EDT NetSol Technologies unveils unified Transcend Platform - NETSOL Technologies announced its new unified Transcend Platform - an AI-powered digital retail and asset finance solution for automotive and equipment OEMs, auto captives, commercial lenders, dealers, brokers and financial institutions. The new NETSOL Transcend Platform offers a robust set of products and solutions under one umbrella, showcasing the company's commitment to harnessing the transformative potential of Artificial Intelligence. The Transcend Platform signifies NETSOL's transformation and adoption of AI technologies for asset finance companies and OEMs. This comprehensive platform addresses various use cases, from asset, auto and equipment finance and leasing technology to innovative digital retail solutions facilitating complex purchasing journeys. NETSOL customers like MINI USA-a subsidiary of BMW-have had significant success with the platform, achieving a 23% increase in average conversion rate from lead to sales over three years.

09:10 EDT Urgently secures three-year contract renewal with customer partner - Urgent.ly announced its three-year contract renewal with a customer partner that operates a global automotive fleet management company. The renewal extends this long-term customer partner relationship to nine years, with Urgently powering the fleet management company's roadside assistance program. With the addition of this customer partner renewal, Urgently has successfully retained all roadside assistance contracts up for renewal since the beginning of the second quarter of 2024, an indication of Urgently's commitment to delivering customer value through exceptional service, cutting edge technology and a prioritization of safety.

09:10 EDT T2 Biosystems, Prxcision announce co-marketing collaboration - T2 Biosystems and Prxcision have announced a co-marketing collaboration intended to deliver a revolutionary solution for patients suspected of bloodstream infections and sepsis, and combat the escalating crisis of antibiotic resistance. "Our platform delivers real-time insights that were once unimaginable," said Paul Ambrose, CEO of Prxcision, Inc. "pRxcision brings cutting-edge AI to the patient's bedside-empowering clinicians to navigate complex decisions with confidence. We are thrilled about this collaboration and believe it can accelerate the adoption of our technology, driving significant improvements in hospitals across the country."

09:08 EDT Fortinet announces general availability of Lacework FortiCNAPP - Fortinet announced the general availability of Lacework FortiCNAPP, a single unified, AI-driven platform to secure everything from code to cloud all from a single vendor. The introduction of Lacework FortiCNAPP offers additional benefits that extend beyond Lacework's leading offering, such as automated remediation and blocking of active runtime threats, as well as enhanced visibility into FortiGuard Outbreak Alerts, which provide key information about new and emerging threats and the risk they pose within an organization's environment.

09:08 EDT WW adds compounded GLP-1, expanding accessibility og weight loss medications - WeightWatchers announced the addition of compounded semaglutide into its offering, broadening eligible members' access to clinical weight management interventions that are underpinned by the comprehensive, science-backed, behavioral and lifestyle support that has helped millions of people reach and sustain their weight goals. "At WeightWatchers, we have always combined proven science and personalized support to help our members achieve meaningful, lasting results. With the addition of compounded semaglutide, we are expanding our offering to include a clinical weight management solution that is both accessible and affordable," said Tara Comonte, Interim CEO of WeightWatchers. "This launch is the culmination of extensive research and rigorous work by our team to ensure that we are offering the highest quality care - reaffirming the trust we've built over six decades as the leader in weight management."

09:07 EDT Baiyu Holdings files Nasdaq delisting appeal notice - BAIYU Holdings has filed timely a formal notice of appeal to a Hearings Panel of a Nasdaq Stock Market Listing Qualifications Staff's determination to delist the company's securities from Nasdaq. BAIYU intends to maintain that the Staff did not consider all relevant facts in making its delisting decision. The Nasdaq Staff based its delisting decision on concerns relating to the substance and timing of the company's recent disclosures regarding a contract for the sale of electric lithium batteries to be purchased from a U.S.-based auto supplier and a letter of intent to build and operate electric vehicle charging stations in Cairo, Egypt. The Nasdaq Staff's articulated concerns relate to the adequacy of the company's due diligence in the transactions and what it considered unusual trading activity in the company's common stock following the announcements. The company has not conducted any marketing or promotional campaigns regarding the company's stock during calendar 2023 and 2024, and no company officer or director traded BAIYU stock in August, September or October 2024. The company continues to take steps to put in place the complementary and component elements of the transaction. The contract represents the official debut of the company's proprietary lithium battery brand into the U.S. market. BAIYU anticipates that its common stock will remain listed on the Nasdaq pending the outcome of the hearing and subsequent decision by a hearings panel. Meanwhile, the company continues to be current with its SEC filings and expects to maintain the registration of its securities.

09:06 EDT iLearningEngines announces launch of Insurtech Enterprise AI Knowledge Cloud - iLearningEngines announced the launch of its Insurtech Enterprise AI Knowledge Cloud and hyper apps aiming to serve the European Insurtech industry. iLearningEngines aims to help private insurers and their industry associations adopt and scale their AI projects, particularly where telematics application development can be accelerated and hyper-automated. This will be achieved by leveraging Generative AI partners such as Genlab Venture Studio, a founding member of CoSAI, Coalition for Safe AI, and global cloud service providers, global systems integrators, assurance and audit partners.

09:05 EDT CaliberCos announces transaction with Satori Collective - Caliber announced that it has reached a definitive agreement with Satori Collective in which Satori will contribute seven hotel properties to Caliber subsidiary Caliber Hospitality Trust, or CHT, an externally advised private hospitality corporation. The transaction is expected to close in early 2025, subject to customary closing conditions. Atlanta-based Satori Collective, formerly known as Banyan Investment Group and founded in 2013, is an investment management firm focused primarily on hotel property investment. The seven Satori properties in this agreement include a mix of middle-market full service, select service and extended stay hotels in the Midwestern and Southern U.S., representing Marriott, Hilton and IHG hospitality brands. The combined portfolio value is approximately $120M.

09:04 EDT RCI Hospitality reports Q4 club & restaurant sales and share buybacks - RCI Hospitality reported club and restaurant sales for Q4. Sales do not include non-core operations and are subject to final closing. The company also reported 4Q24 and FY24 share buybacks. In nightclubs, total Q4 sales of $60.2M declined 0.5% vs. 4Q23. The change primarily reflected: 2.2% same-store sales growth, which was negatively impacted by ten closure days at three clubs in the Houston area due to Hurricane Beryl in July; sales from three new and reformatted clubs in Texas; the temporary closing of two clubs in Texas for most of the quarter; the transition of two clubs to new formats and/or hours to accommodate recent restrictions on Dallas businesses. In Bombshells, total 4Q24 sales of $11.9M declined 12.2% vs. 4Q23. The change primarily reflected a 16.2% same-store sales decline, negatively impacted by 26 closure days at five locations in the Houston area due to Hurricane Beryl in July; new sales from the Stafford location, which opened in November 2023, partially offset by a decline in sales from the San Antonio location, which was sold at the beginning of September. RCI repurchased 174,790 common shares for $7.8M at an average of $44.81 per share, resulting in 8,955,000 shares of common stock outstanding and $21.0M in remaining purchase authorization. In FY24, RCI repurchased 442,639 shares for $20.6M at an average of $46.55 per share.

09:04 EDT Colorado School of Mines, Carbon TerraVault awarded $8.9M in DOE funding - Colorado School of Mines and Carbon TerraVault Holdings, a subsidiary of California Resources, announced the award of $8.9 million from the U.S. Department of Energy, DOE, for a Carbon Storage Assurance Facility Enterprise, CarbonSAFE, project in California. The grant will allow Mines, CTV, and industry partners Blade Energy Partners and Providence Strategic Consulting to conduct a feasibility study on the CTV III CO2 Storage Project, an underground carbon storage reservoir in San Joaquin County, California. The project will store up to an expected 71 million metric tons of carbon emissions.

09:02 EDT Broadcom to highlight solutions at 2024 Open Compute Project Global Summit - Broadcom announced that momentum continues to build in support of its vision of enabling AI infrastructure through a combination of open standards, scalability, and power efficient solutions. Broadcom will highlight advancements across the areas via a series of presentations, product demonstrations, and other forums at the 2024 Open Compute Project Global Summit. The 2024 Summit takes place in San Jose, Calif. from Oct. 15-17. At the summit several cutting-edge AI solutions will be featured including: Ethernet networking switches like the Tomahawk 5 and Jericho3-AI designed to accelerate AI/ML workloads. The Trident4-X11 Ethernet switch engineered to create the front-end fabric that interfaces with the back-end AI fabric. Tomahawk 5 - Bailly, the world's leading 51.2 Tbps CPO Ethernet switch, which combines advanced silicon photonics CPO technology with Broadcom's Tomahawk 5 switch chip, setting a new benchmark for power efficiency and performance in AI infrastructure. High-performance, low-power 400G PCIe Gen 5.0 Ethernet adapters, developed as open, standards-based solutions to address connectivity challenges as XPU bandwidth increases and AI data center clusters expand. PCIe Gen 5.0 switches, which are the open, standards-based fabric of choice for AI connectivity; drawing half the power of alternatives, with industry leading SerDes, telemetry and diagnostics. The industry's first PCI Express Gen5/Gen6 retimers, offering ultra-low power solutions to enhance efficiency and scalability in AI infrastructure. Sian and Sian2 DSPs, supporting 200G/lane pluggable modules for connecting next-generation AI clusters.

08:57 EDT PharmAla to supply University of Texas, San Antonio with LaNeo MDMA - PharmAla Biotech has been contracted as a supplier of MDMA to a proposed clinical trial at the University of Texas, San Antonio. Pursuant to a submitted grant funding application by the principals, the contract envisions the creation of a new dosage form for LaNeo MDMA, which will subsequently be tested in an investigator-initiated human clinical trial.

08:55 EDT Ondas appoints Markus Nottelman as senior advisor - Ondas Holdings announced that Markus Nottelmann has joined the Company as Senior Advisor, focusing on commercial development and strategic activity for Ondas' wholly-owned subsidiary Ondas Networks, where he will also serve as a board member. Nottelmann is an accomplished executive and brings a wealth of experience through holding various financial and operating roles including leadership positions with Sperry Rail Service and Acuren Inspections, both subsidiaries of Rockwood Holdings, LP, as well as Furmanite Inc. and DMA S.r.l. Since 2020, Markus has been applying his broad experience as strategic CFO, leading several companies through strategic assessments, transformations, and acquisitions.

08:52 EDT American Resources' ReElement appoints Yi Ding as CTO - American Resources announced that its wholly owned subsidiary, ReElement Technologies, has appointed Dr. Yi Ding, Ph.D., as Chief Technology Officer. Dr. Ding joined ReElement Technologies in the summer of 2022 as the Company's Director of Research and Development.

08:49 EDT Sparta Commercial Services reports results with early EzBroker360 adopters - Sparta Commercial Services announced that its subsidiary, Agoge Global USA and its joint venture partner, WeDev Group Ltda., experienced a notable increase in the number of client transactions processed on its EZBroker360 platform since its July 31, 2024 quarter end launch. "We are thrilled to see strong market adoption almost immediately after the launch of our platform," said Anthony Havens, CEO. "Our team continues to work diligently to disrupt an untapped sector of the import/export industry, and the positive response from our clients is a testament to our efforts. This has led to requests from current clients to expand their relationship and a growing backlog of prospects queuing up to get on the platform." Our platform combines a Merchant of Record model with a comprehensive suite of services that simultaneously improves the efficiency, reduces the cost, and increases the speed of the financial management process for Brazilian importers and exporters. Introduced just a few short months ago, our platform has been successfully implemented at a number of trading organizations for a range of services, including the seamless integration of invoice management, bill of lading processing, and import/export declarations, along with a robust staged financing module. In fact, several transactions are on the precipice of completing a 'full loan cycle,' where clients will have received and repaid critical import/export costs funded through our platform. Having proven commercial success with these initial implementations, the Company will now begin onboarding additional clients as our bandwidth grows.

08:48 EDT M2i Global, Global Remediation, Linecrest enter licensing agreement - Global Remediation Inc, in collaboration with M2i Global announced a Licensing agreement facilitated by Komodo Capital with Australia's Linecrest. This agreement aims to revolutionize and enhance the sustainability and security of critical mineral supply chains.M2i's ecosystem provides partners with access to turnkey solutions, facilitating expanded business opportunities, securing offtake agreements, influencing strategic government policy, engaging with aligned NGOs, and trusted laboratories. Linecrest in collaboration with its research and development partner Nova Terra Limited and Australian Universities, is a leading provider of innovative mineral processing technology. Together, they have developed a proven, cutting-edge technology in Australia that is now entering the next stage of commercialization. Their advanced processing methodology, which integrates X-Ray fluorescence and infrared technology to detect and sort minerals at a commercial scale, has demonstrated its ability to increase mining efficiencies and reduce highly contaminated waste by over 30%.

08:47 EDT Oragenics completes key FDA-recognized study for ONP-002 - Oragenics has completed a key study for their new concussion drug, ONP-002. This drug is designed to be delivered through the nose, which could help it reach the brain quickly after a head injury. The recent study shows that the drug successfully targets areas inside the nose that are connected to the brain. This makes it more likely to reach and treat the brain after a concussion. Intranasal casting studies are valued by the FDA for pharmaceuticals delivered via the nasal passage and accept such studies in FDA submissions. Oragenics is now preparing to move forward with human testing in patients who come to the emergency room with a concussion, aiming to give the first dose of the drug within 8 hours of the injury.

08:46 EDT Yoshiharu enters partnership with Xing Sheng Group - Yoshiharu Global entered into a non-binding Memorandum of Understanding with Xing Sheng Group through a Master License Agreement for the Liaoning Province in China to introduce a new flagship Yoshiharu restaurant in Shenyang, China, home to over 43 million people. Founded in 1991, Xing Sheng Group is a prominent Chinese conglomerate with ventures in real estate, investments, and film production, operating 17 subsidiaries in major cities across China. Its real estate arm, Shenyang Yongsheng Seven Stars Tourism Development, specializes in developing tourist attraction centers in Shenyang and is currently constructing China's largest water park. This strategic partnership offers Yoshiharu a prime opportunity to develop a location within the water park, catering to both local residents and visiting tourists. As the capital and largest city of China's northeast Liaoning Province, Shenyang is a dynamic transportation and commercial hub of northeast China, positioning the new flagship location to serve the ethnically and culturally diverse population. Following Yoshiharu's recent expansion into Las Vegas, this flagship location in Shenyang will play a pivotal role in advancing the Company's growth strategy by introducing and expanding the Yoshiharu brand and its culinary offerings to new markets.

08:45 EDT Runway Growth Finance provides Q3 portfolio update - Runway Growth Finance provided an operational and portfolio update for the third quarter ended September 30, 2024. Originations: In the third quarter of 2024, Runway Growth funded seven investments: two investments in new portfolio companies and five investments in existing portfolio companies. These include: Completion of a new $23.0 million investment to Snap! Mobile; Completion of a new $45.3 million investment to Zinnia Corporate Holdings; Completion of a new $20 million investment to existing portfolio company Elevate Services; Completion of follow-on investments with an aggregate amount of $6.3 million to two existing portfolio companies; and During the quarter Runway-Cadma I, its joint venture with Cadma Capital Partners LLC, purchased a portion of its Airship Group, Inc. loan, amounting to a $5.0 million equity investment in the JV subsidiary. During the third quarter ended September 30, 2024, Runway Growth experienced the following liquidity events: Full principal repayment of the Company's senior secured term loan to CloudPay, Inc. of $75.0 million; An assignment of $10.0 million of the Company's investment in Airship Group, Inc. to the JV; and Other scheduled principal amortization of $0.6 million.

08:43 EDT Roblox down 10% after called 'pedophile hellscape' in Hindenburg short report

08:42 EDT Seanergy Marine mails CEO letter to shareholders - Seanergy Maritime Holdings announced that it has mailed a letter from Stamatis Tsantanis, Seanergy's Chairman and Chief Executive Officer, to shareholders in connection with the Company's upcoming 2024 Annual Meeting of Shareholders. The letter highlights the Company's: Transformation over the last four years into a prominent pure-play Capesize shipping company with attractive competitive positioning and an improved balance sheet, poised to capitalize on tailwinds in the Capesize market; Comprehensive strategic plan that has enabled Seanergy to grow its business, deliver record financial results and increase returns to shareholders; and qualified directors who each brings a deep understanding of the industry. Their continued oversight is critical for us to build on our momentum and execute our strategic plans. The Seanergy Board of Directors continues to unanimously recommend that shareholders vote on the WHITE proxy card "FOR" Seanergy's nominees and "AGAINST" the proposals made by Economou, and discard any other proxy card you may receive from Economou.

08:42 EDT Kopin gets order for SXGA-R15 microdisplay system for 3D AOI, no terms - Kopin Corporation announced that it has secured its first production purchase order for the recently launched SXGA-R15 microdisplay system for 3D Automated Optical Inspection or 3D AOI . This initial order comes from Mirtec of South Korea..."This order from Mirtec is evidence that with the low-cost and small form factor advantages offered by the SXGA-R15 system, we believe Kopin is well positioned to capitalize on this surge in demand across Asia and other global markets," said Greg Truman, Vice President of Business Development for Europe and Asia. "Kopin's SXGA-R15 is particularly well-suited for high-growth sectors like semiconductor manufacturing and automotive electronics, where the demand for high-precision 3D inspection continues to rise. We are excited to support Mirtec's continuing innovation in 3D AOI and contribute to enabling their next generation of automated inspection machines."

08:39 EDT OncoCyte's DetermaIO predicts response to Atezolizumab in Phase 2 trial - Oncocyte announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO. The NeoTRIP Phase 2 clinical trial randomized patients with triple-negative breast cancer, TNBC, to receive neoadjuvant carboplatin and nab-paclitaxel, with or without the immunotherapy, atezolizumab. As a secondary point of interest in the study, Oncocyte's DetermaIO test was among several established biomarkers and gene signatures assessed for its ability to predict which patients with early stage TNBC are most likely to benefit from the immunotherapy. The study was performed in collaboration with the Michelangelo Foundation for Cancer Research, a well-regarded independent scientific organization based in Milan. Only DetermaIO was both statistically significant and predictive of a pathologic complete response among the various biomarkers assessed.

08:38 EDT Richtech Robotics signs distribution agreement with Sproutmation - Richtech Robotics has signed a distribution agreement with Sproutmation. Sproutmation's first purchase order is for 20 Scorpion units. Under the arrangement, Sproutmation has agreed to an annual sales target of 100 robot units.

08:37 EDT CytoDyn appoints Max Lataillade as head of clinical development - CytoDyn announced that Max Lataillade, DO, MPH, has been appointed as Senior Vice President and Head of Clinical Development. Under his consulting agreement, Dr. Lataillade will lead the Company's global research and development strategy and oversee end-to-end R&D activities to advance the Company's clinical development pipeline. He most recently served as Vice President, Head of Early Development and Global Research Strategy at ViiV Healthcare.

08:35 EDT ECD Automotive Design launches retail strategy, site selection process - ECD Automotive Design announced it has embarked upon a new retail strategy to own and operate brick and mortar showrooms to market and sell ECD's vehicles. In support of the strategy, ECD has signed an agreement with Site Selection Group, of Dallas, Texas, to research and identify real estate locations to effectuate ECD's retail showroom concept. The Company anticipates three avenues to generate additional revenue at a retail location: a customer signs for a new, custom build and begins the process that allows for over 2 million design choices, a customer purchases an existing ECD new car that is available for immediate delivery and a customer purchases a used ECD vehicle from ECD.

08:34 EDT Hub Group enters joint venture with EASO - Hub Group announced that it entered into a joint venture with EASO. Transaction Highlights: Unique partnership adds significant scale to Hub Group's intermodal business and drayage capabilities in Mexico; expands physical footprint via EASO's network of terminals; Joint venture will be the largest cross-border and intra-Mexico intermodal company, positioning Hub Group to capitalize on nearshoring trends and providing meaningful growth opportunities; EASO has been expanding its cross-border presence and converting over-the-road freight to intermodal, resulting in over 30% YoY intermodal volume growth; Sizable synergy opportunities associated with cross-selling, operational integration, asset utilization and drayage enhancements; Immediately accretive upon close to Hub Group's 2024 EPS prior to expected cross-sell and operational synergies

08:34 EDT BlackSky awarded seven-figure contract to deliver NEI services - BlackSky won a seven-figure contract to deliver non-Earth Imaging, or NEI, services to support the customer's Space Domain Awareness, or SDA, capabilities. As part of the contract BlackSky will integrate Gen-2 satellite imagery of on-orbit spacecraft into the customer's collection of SDA assets.

08:32 EDT Portillo's partners with Milk Bar for Chocolate Cake Cookie - Portillo's and Milk Bar have teamed up to create a limited-edition treat, the Portillo's Chocolate Cake Cookie. Starting Tuesday, Oct. 8, the limited-edition, individually-wrapped Portillo's Chocolate Cake Cookie will be available for purchase inside at all Portillo's restaurants with dining rooms via the grab-and-go display. In addition, a six-count Cookie Tin will be available for nationwide shipping at MilkBarStore.com, while supplies last.

08:21 EDT Cassava Sciences to announce top-line results of ReTHINK trial before year-end - In a regulatory 8-K filing, the company publishes the letter from its CEO Rick Barry, stating: "A lot has happened in the few months since I last wrote to you. It's time that I update you on what has taken place here at Cassava and the substantial progress that we have made. I am happy to inform you that our ReTHINK Phase 3 clinical trial recently completed its last patient, last visit. All patients have completed dosing, and all that remains is to collect and analyze the data. For a company our size, this is a remarkable achievement. This study enrolled 804 patients at 77 sites in the US, Puerto Rico, Canada, and Australia. Patients were randomized 1:1 between placebo and simufilam 100 mg, twice daily. Approximately 70% of the patients entered the study with mild Alzheimer's disease, while 30% entered with moderate Alzheimer's. We expect to announce top-line results of the ReTHINK trial before year end. We submitted our proposed Statistical Analysis Plan to FDA in July and are now responding to comments that we have received from the agency. We expect to finalize the Statistical Analysis Plan in the near term." Reference Link

08:19 EDT GSE Systems says received non-binding indication of interest - In a regulatory filing, GSE Systems announced that on October 1, after business hours, the company received a non-binding, unsolicited letter from a third party that stated Company Z was prepared to offer $5.50 to $5.75 per share for the company's common stock. Company Z requested that the company enter into "exclusivity" with company Z to allow 17-21 days to conduct due diligence and negotiate a definitive agreement. The Board of Directors of the company met with representatives of Robert W. Baird & Co. Incorporated and Miles & Stockbridge P.C. on Wednesday, October 2, 2024, to assess the letter. The Board instructed its representatives to seek clarification and ascertain whether the letter was a Takeover Proposal that was likely to lead to a Superior Proposal. The company then provided Parent with all required notifications under the Merger Agreement. The same day, representatives of Baird and M&S contacted a representative of Company Z to clarify the terms of the letter. Among other things, the company's representatives notified Company Z that the terms of its letter were inconsistent with Section 5.2 of the Merger Agreement and the best interests of the company's stockholders. Further, it became clear that Company Z lacked an understanding of the full extent of the transaction value. A representative of Baird informed Company Z that it would need to enter into an Acceptable Confidentiality Agreement and conduct expedited due diligence. Shortly after the call, a representative of M&S provided Company Z with a draft confidentiality agreement. While the Board was prepared to enter into an Acceptable Confidentiality Agreement and provide information to Company Z as permitted by Section 5.2(b) of the Merger Agreement, Company Z did not take any further action. On Thursday, October 3, 2024, a representative of M&S emailed Company Z to inquire as to status and to remind Company Z that time is of the essence. Company Z provided no response. On Friday, October 4, 2024, a representative of M&S again emailed Company Z to inquire as to status. In response, a representative of Company Z advised that it did not agree with the requirements of an Acceptable Confidentiality Agreement or an expedited diligence process. In response, a representative of M&S advised that Baird and M&S were available to review any comments to the draft confidentiality agreement and then address concerns related to a potential process. Company Z provided no further response. In light of the foregoing, the Transaction Committee held a meeting the afternoon of October 4, 2024. The Transaction Committee discussed prior non-binding indications of interest received from third parties, including those reflected in the Background of the Merger section of the Company's proxy statement on Form DEFM14A, prior negotiations with Company A, prior negotiations with Company B and prior negotiations with Company D, each of which had conducted extensive due diligence. After discussing that each of the foregoing parties had submitted non-binding offers or indications of interest, but later withdrew from the process after receiving access to due diligence, and also citing Company Z's failure to comply with the procedural requirements set forth in the Merger Agreement, the Board expressed concern that Company Z's non-binding proposal appears unlikely to mature into a binding Takeover Proposal, much less a Superior Proposal. GSE reaffirms its recommendation that the stockholders approve the merger agreement with Parent at the October 25 special meeting.

08:17 EDT Ensysce leadership participates at Annual Pain Therapeutics Summit - Ensysce Biosciences announced that Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, will present at the 18th Annual Pain Therapeutics Summit taking place on October 28 and 29, 2024 in Boston, MA. Dr. Kirkpatrick's presentation "When All You Have is a Hammer ... A New Approach to Soften the Blow" will be held on Monday, October 28th at 1:00 PM Eastern Time. In this session, Dr. Kirkpatrick will review the proliferation of new analgesic entrants that have promised opioid-like efficacy but to date have not delivered. The result has been opioid mistrust and unfortunately, a reduction in access for those who depend on opioid pain relief for a decent quality of life. Instead of turning away from these effective analgesics, Ensysce embraced their efficacy by introducing new TAAP and MPAR classes of opioids. The lead agents, PF614 and PF614-MPAR, are expected to provide a novel option for high-risk patients delivering exquisite pain relief yet with advantages over currently used Abuse Deterrent Formulation opioid products. TAAP-modified opioids reduce multiple forms of abuse and only release the opioid when taken orally and exposed to trypsin in the gut. MPAR applies another layer of safety resulting in oral overdose protection by adding a trypsin inhibitor to each of the TAAP products. Dr. Kirkpatrick will present clinical data demonstrating these unique qualities of TAAP and MPAR and supporting their added benefits over the ADF class.

08:16 EDT Infosys, Old National Bancorp expand collaboration - Infosys (INFY) and Old National Bank (ONB) recently entered into a strategic expansion of their four-year collaboration. This deepening of a highly successful relationship enables Old National to leverage Infosys services, solutions and platforms for operations transformation and process digitization powered by automation and GenAI, and transformation of key business areas. Since 2020, Infosys has helped Old National modernize its digital landscape using a highly efficient, self-funding model. The resulting uplift in stability, resiliency and improved client experience has served to accelerate and sustain Old National's growth.

08:14 EDT aTyr Pharma to present on efzofitimod for pulmonary sarcoidosis at CHEST 2024 - aTyr Pharma announced that the Company's lead therapeutic candidate, efzofitimod, will be featured in the Best of CHEST Journals session at the CHEST 2024 Annual Meeting, which is scheduled to take place October 6 - 9, 2024, in Boston, MA. "We are very pleased to have efzofitimod featured in this year's Best of CHEST session, which speaks to the high quality of the data from the Phase 1b/2a study that was previously published in the journal," said Sanjay Shukla, CEO. "We believe the findings from this study, which showed the ability of efzofitimod to reduce-and in some cases eliminate- steroid use in patients while controlling symptoms, are an important step forward in developing a potential new treatment for sarcoidosis." The presentation will review data supporting the efficacy of efzofitimod in pulmonary sarcoidosis, including findings from a Phase 1b/2a study for key efficacy endpoints including measures of steroid reduction, lung function, sarcoidosis symptoms and inflammatory biomarkers that were published in CHEST and a post hoc analysis of the Phase 1b/2a study that evaluated time-to-first-relapse and relapse rate for steroid use that was published in the European Respiratory Journal. Efzofitimod is currently being investigated in the global pivotal Phase 3 EFZO-FIT study in 268 patients with pulmonary sarcoidosis. Topline data from the study are expected in the third quarter of 2025.

08:13 EDT Asset Entities announces new episode on "The Lounge" podcast - Asset Entities announced their next episode on the Lounge featuring former National Champion Miami Hurricanes, Michael Irvin and Sandy Jack. This episode will feature Irvin and Jack, who discuss their journey as teammates at the University of Miami, playing football for famed head coach Jimmy Johnson, winning a national championship with the Hurricanes, and other life lessons. "The Lounge" is hosted by well-known TikToker, Kyle Fairbanks, who also serves as the Executive Vice Chairman and Chief Marketing Officer for Asset Entities. The Lounge can be viewed on its YouTube channel @TheAELounge.

08:12 EDT Parex Resources reports Q3 average production 47,569 boe/d - Q3 2024 Production Update: Q3 2024 average production was 47,569 boe/d. Average production was in line with the most recent production guidance. September 2024 production was supported by a new well at Capachos. Parex's production guidance incorporates a range of technical outcomes and contingency for significant downtime events; there were no notable downtime events during the quarter.

08:10 EDT Kartoon Studios, Samsung TV Plus launch kids free streaming channel - Kartoon Studios (TOON) announced it has launched Kartoon Channel's videogame FAST channel through Samsung (SSNLF) TV Plus in three large European territories - the UK, Italy, and Spain. In addition, through a joint venture with Power Kids, Kartoon Channel will be offered in India, one of the largest television markets in the world. These new territories will immediately provide Kartoon Channel with a footprint of over 1.5 billion new viewers.

08:08 EDT Regulus completes enrollment in fourth cohort of Phase 1b kidney disease trial - Regulus has completed enrollment of 26 patients in the fourth cohort in the Phase 1b MAD study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease, or ADPKD. The trial remains on track for an End of Phase 1 meeting with the FDA by the end of 2024, and Regulus plans to share topline data from a substantial number of patients in cohort four in early 2025. The Phase 1b MAD study is fixed dose trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RGLS8429 in adult patients with ADPKD. The study is evaluating RGLS8429 treatment across three different weight-based dose levels and one fixed dose level.

08:06 EDT Converge selects Infinera's 1.2T ICE7 - Infinera announced that Converge ICT Solutions selected Infinera as its submarine line terminal equipment vendor for the fiber pairs over which Converge has been granted an Indefeasible Right of Use on the Bifrost Cable System, using Infinera's GX Series Compact Modular Platform and its next-generation high-performance 1.2T ICE7 optical engine. Additionally, Converge will use Infinera's solutions to modernize its nationwide terrestrial fiber network across the Philippines.

08:06 EDT NV5 Global announces acquisition of Kisebach Consulting, Senergy BCS - NV5 Global announced the acquisition of two domestic data center commissioning and energy management companies, Kisebach Consulting and Senergy BCS, to further accelerate NV5's strong organic growth in the data center market. "NV5's data center business continues to deliver double digit organic growth, and we see an opportunity to accelerate that organic growth, particularly in the domestic data center market," said Ben Heraud, Chief Executive Officer of NV5. "The key to expanding our highly profitable data center business is to provide clients with the leading technical expertise to meet the growing demand for artificial intelligence data center capacity, cooling, and energy efficiency. Senergy BCS and Kisebach Consulting provide decades of data center-specific experience and relationships with some of the nation's leading data center owners and operators, and we look forward to the contributions they will make to our data center business."

08:04 EDT CorMedix announces new commercial agreement with mid-sized dialysis operator - CorMedix announced that it has entered into a new commercial supply contract with a top-five mid-sized dialysis operator for the supply of DefenCath to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 200 outpatient dialysis clinics located across the United States. "This new agreement, in combination with our existing customer agreements, gives CorMedix the opportunity to make DefenCath available to patients receiving hemodialysis though a CVC at roughly 60% of the outpatient dialysis centers in the US," says CorMedix CEO, Joseph Todisco. "We are working closely with all of our new customer relationships on the operational steps needed to ensure DefenCath availability in their clinics in the coming months."

08:04 EDT SolarBank to develop 13.8 MW DC ground-mount solar power project - SolarBank is excited to announce its plans to develop a 13.8 MW DC ground-mount solar power project known as the Grandview project on a site located in Lancaster County, Pennsylvania. The Project is part of a three-project plan totalling 24.8 MW DC. The proposed community solar project - which would be one of the first of its kind in Pennsylvania - would provide residents, including renters and those without suitable rooftops, with the opportunity to benefit from solar energy without the need to install panels on their own properties. The company has secured a lease over the Project site and will continue to work to complete the next steps in permitting, interconnection and securing the necessary financing for construction of the Project. The development of the Project as a community solar project will be subject to the final approval of House Bill 1842 by the State government of Pennsylvania.

08:02 EDT Lipocine signs supply and distribution agreement with Pharmalink for Tlando - Lipocine announced an exclusive supply and distribution agreement with Pharmalink to commercialize Tlando, its oral testosterone replacement therapy, in the Gulf Cooperation Council countries consisting of Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman. Under the terms of the agreement, Lipocine received an upfront payment from Pharmalink and, upon Marketing Authorizations in individual GCC countries, Lipocine will provide Tlando drug product to Pharmalink at an agreed transfer price. Pharmalink will have the exclusive rights to Tlando throughout the GCC region and will be responsible for promotion, distribution and sale of the product in the territory.

07:47 EDT Jacobs to operate and maintain advanced water reuse facility in California - Jacobs secured a 10-year contract with Soquel Creek Water District to operate and maintain a new advanced water purification facility. The facility, part of SqCWD's Pure Water Soquel program, focuses on groundwater replenishment and seawater intrusion prevention in Santa Cruz County, California. The new facility will treat municipal secondary effluent to replenish SqCWD's sole drinking water source, the Santa Cruz Mid-County Groundwater Basin. The advanced water purification facility will provide sustainable drinking water for the traditionally drought-stressed region. Optimizing the plant will also reduce ocean discharge by up to 25%. Jacobs has served as the operations and maintenance at-risk consultant for the advanced water purification facility since 2020. Under the new contract, Jacobs will use its Digital OneWater suite of solutions to improve the plant's performance and mitigate risk.

07:44 EDT Innovation Beverage announces nationwide availability of Australian Bitters - Innovation Beverage Group announced that through its U.S. distributor, Buettner Global Services, IBG's Australian Bitters is now available nationwide in the United States through Sysco.

07:43 EDT ZenaTech's ZenaDrone commences operations to launch commercial drone services - ZenaTech announced that its subsidiary, ZenaDrone, has commenced aerial operations to launch commercial drone services in the US. This was made possible due to recently achieving Federal Aviation Authority, FAA, exemption approval. ZenaDrone will be setting up Drone-as-a-Service operations, initially through its Phoenix, Arizona office, making its drone hardware and software solutions available to customers for use in land surveying, inspection, monitoring, tracking, and other applications using the ZenaDrone 1000 product. "After over a year and a half of application submission and approval timelines, and preparation to ensure we can operate in compliance with FAA requirements, we are excited to be able to commence operations for commercial services and revenue generation in the US," said CEO Dr. Shaun Passley, Ph.D. "We are hopeful this work will pave the way for similar regulatory approvals in additional countries where we've applied and seek to operate in the future."

07:40 EDT FTI Consulting's Technology segment launches IQ.AI for legal, compliance - FTI Consulting announced that the firm's Technology segment has launched IQ.AI by FTI Technology, artificial intelligence solutions that address a range of client issues across disputes and investigations, antitrust and data breach response. FTI Technology's digital insights and risk management experts, attorneys, data scientists and consultants designed and deliver IQ.AI as a proprietary combination of workflows and expertise for applying industry-leading AI technologies in legal and regulatory matters. With IQ.AI, FTI Technology helps clients balance innovation, technology performance and risk mitigation for specific AI use cases. Offerings include: IQ.AI for Investigations: Includes document summarization to quickly and defensibly generate overviews, extract key facts, develop case chronologies and enhance human review. IQ.AI for Data Breach: Enables the quick identification and extraction of personally identifiable information, personal health information and other sensitive data for breach response and data protection compliance during legal and regulatory document productions. IQ.AI for Antitrust: Features can include monitoring in support of compliance with antitrust and other regulations, including oversight for prohibited behaviors within enterprise communications platforms and chat applications and customized analytics to reduce risk across large complex datasets.

07:38 EDT Tourmaline Bio forms Cardiovascular Scientific Advisory Board - Tourmaline Bio announced the formation of its Cardiovascular Scientific Advisory Board. The CV SAB is expected to provide strategic guidance and expertise as Tourmaline advances its pacibekitug cardiovascular diseases program, including the TRANQUILITY Phase 2 clinical trial that commenced earlier this year and for which Tourmaline continues to expect topline data in the first half of 2025. The CV SAB brings together academic and industry veterans with significant experience in cardiovascular medicine, clinical trial design and execution, and therapeutic innovation. Their insights and guidance are expected to be instrumental in shaping the strategic direction of Tourmaline's cardiovascular program as the company prepares for Phase 3 clinical trial readiness in 2025, supporting efforts to redefine standards of care for high-risk cardiovascular disease patients. Cardiovascular Scientific Advisory Board Members: Joshua Beckman, MD, MSc - UT Southwestern Medical Center; Marc Bonaca, MD, MPH - University of Colorado, CPC Clinical Research; Robin Choudhury, MA, DM, FRCP - University of Oxford; Douglas L. Mann, MD - Washington University School of Medicine; James Min, MD - Cleerly, Inc.; Pradeep Natarajan, MD, MMSc - Massachusetts General Hospital; Michael D. Shapiro, DO, MCR - Wake Forest University School of Medicine; Michael Szarek, PhD - University of Colorado, CPC Clinical Research.

07:37 EDT Electra Battery Materials to participate in OECD Conference - Electra Battery Materials announced CEO Trent Mell will be participating in the 2024 OECD Conference of Mining Regions and Cities taking place October 8 to 11, 2024, in Greater Sudbury, Canada. The OECD is a forum and knowledge hub for data, analysis and best practices in public policy. This conference brings together stakeholders from across the public and private sectors, academia, civil society organisations, and Indigenous representatives, this year focusing on partnering for sustained development in mining regions and future-proofing regional mineral supply for the energy transition. Mr. Mell will be speaking as part of a panel discussion, as well as meeting with industry and other stakeholders during the conference. The panel, titled Advancing circular practices to increase local added-value, will discuss unlocking new business opportunities, notably circular economy strategies such as recycling. Electra CEO, Trent Mell said, "I am looking forward to participating in these important discussions. The OECD Conference of Mining Regions and Cities is an opportunity for stakeholders from various levels of government, locally and globally, along with industry and community representatives to come together to collaborate on solutions for building a greener future. Electra is committed to helping build a sustainable, North American battery materials supply chain, reducing reliance on foreign sources."

07:36 EDT Vivos granted CPT coverage, reimbursement codes for all Vivos CARE devices - Vivos Therapeutics announced the American Medical Association, AMA, has issued new CPT medical codes applicable to all Vivos CARE oral medical devices, which will become effective January 1, 2025. Vivos Chairman and CEO, Kirk Huntsman, stated, "This is exciting news for OSA patients and medical providers who treat sleep breathing disorders. Our CARE oral medical devices are the only ones cleared by the U.S. Food and Drug Administration for the treatment of moderate to severe OSA, and these new medical codes will now facilitate coverage and reimbursement by commercial medical insurance payers. From Vivos' perspective, we believe this will enable a larger number of patients from most demographics to access our breakthrough, proprietary airway remodeling technology and more effectively treat their OSA. This development comes at an opportune moment for Vivos as our recent regulatory approvals, coupled with our new alliance-based marketing and distribution model and now these new codes put Vivos in an improved position to drive revenue growth."

07:34 EDT Stardust Power, KMX Technologies enter 90-day exclusivity period - Stardust Power and KMX Technologies announced that it has entered into a 90-day exclusivity period during which Stardust Power and KMX will negotiate the terms and conditions related to Stardust Power's exclusive use of lithium brine concentration technology from KMX. The transaction is subject to the negotiation and execution of definitive documentation and the parties' mutual board approvals.

07:32 EDT Sphere Entertainment EVP, CFO and Treasurer David Byrnes leaving the company - Sphere Entertainment announced that David Byrnes, EVP, CFO and Treasurer, will be leaving the company. The company will commence a search for a new CFO and Treasurer. Byrnes will continue in his current role for an interim period to facilitate a smooth transition. Byrnes has served as EVP, CFO and Treasurer of the company since December 2023. Prior to that, he served as EVP and CFO of Madison Square Garden Entertainment from January 2022 to December 2023.

07:32 EDT Siga Technologies enters agreement to supply TPOXX in Morocco - SIGA Technologies entered into an agreement to supply TPOXX in Morocco. The contract was executed in response to a request from the Ministry of Health in Morocco to make the therapy available in the country and help prepare and protect its citizens against any potential mpox outbreak. Tecovirimat is approved in the U.S., Canada, and the EU, and while it has also been available in Africa through clinical trials and as part of the World Health Organization's emergency use access protocol, this agreement marks SIGA's first commercial sale of TPOXX on the continent.

07:15 EDT Laser Photonics comments on stock volatility amid short report - Laser Photonics commented on recent business updates and trading activity. The company said, "The Company believes positive news surrounding LPC, particularly the excitement generated by the LSAD concept, contributed to significant stock volatility in September. LPC shares rose from $3.29 on September 3 to an intraday high of $19.80 on September 23. This price movement attracted the attention of short sellers. LPC recently became aware of a short report published after the writer had already taken a short position, attempting to manipulate the stock price for profit. The Company is actively exploring legal options and wishes to clarify the following: The report centers on allegations involving an individual affiliated with, but not employed by, or a director of, LPC. This individual is not involved in the Company's day-to-day operations. The individual referenced has never been convicted of any felony, including the claims made in the report. The report was released post short-positioning, suggesting an intent to manipulate the stock price downward for personal gain. LPC remains committed to providing shareholders with transparent and timely updates as the Company continues to grow across its core business segments."

07:14 EDT Calian secures new contracts for nuclear, environmental services division in Q4 - Calian Group secured a number of new contracts in the fourth quarter for its nuclear and environmental services division, marking significant growth in the last quarter of FY2024 ending on September 30. The new contracts-19 in total-represent a 58% increase over Q3 FY2024, primarily driven by the successful integration of MDA's nuclear assets and strong organic growth. The acquisition of MDA's nuclear division in March 2024 has allowed Calian to capitalize on increased synergies across its nuclear business, through the addition of engineering, tooling and robotics expertise, enhancing its capacity to deliver comprehensive, end-to-end solutions for Canada's growing nuclear sector. The new contracts span major new nuclear projects in Ontario, Saskatchewan and New Brunswick, supporting life-extension programs for Canada's existing nuclear facilities and support for next-generation technologies like small modular reactors (SMRs). This expansion has also led to a doubling of the division's workforce to meet the growing demand for FY2025.

07:13 EDT Canadian Natural raises quarterly dividend by 8% to C$0.5625 per share - Canadian Natural (CNQ) "announces that, in conjunction with the acquisition of Chevron (CVX) Canada Limited's Alberta assets and as a result of Canadian Natural's significant free cash flow, including targeted additional free cash flow generation from the acquired assets and the Company's strong financial position, the Board of Directors have agreed to increase the quarterly cash dividend by 7% to $0.5625 per common share, up from the previous quarterly cash dividend of $0.525 per common share. The dividend will be payable on January 3, 2025 to shareholders of record at the close of business on December 13, 2024. This will make 2025 the 25th consecutive year of dividend increases by Canadian Natural, with a CAGR of 21% over that time."

07:12 EDT Optimi Health appoints Parisa Zamiri as CMO, Tom Reilly as CFO - Opthea (OPTHF) announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. Parisa Zamiri, MD, PhD has been appointed Chief Medical Officer, effective October 7, 2024, reporting to Frederic Guerard, PharmD, CEO, Opthea. She will oversee clinical development and operations, regulatory and medical affairs, as well as biometrics. She most recently served as the CMO at Complement Therapeutics. Tom Reilly has been appointed CFO, effective October 28, 2024, reporting to Frederic Guerard.Before joining Opthea, Mr. Reilly served as CFO and Head of Human Resources of Amarin Corporation (AMRN), supporting the commercial expansion of the company's lead asset in cardiovascular disease. Anand Sundaram has been appointed Vice President Marketing, effective October 14, 2024, reporting to Mike Campbell, Chief Commercial Officer, Opthea. He joins the Company from Astellas where he served in commercial strategy and market access leadership roles to drive the successful launch of Izervay in geographic atrophy.

07:11 EDT European OEM selects Aeva for automated vehicle validation program - Aeva announced that a major European passenger vehicle OEM, together with a simulation and validation technology leader, will use Aeva's 4D LiDAR technology in its automated vehicle development program. Aeva's Aeries II sensors will gather ground truth data, considered to be the "gold standard" in environmental modeling, to provide the OEM with accurate data to validate its next-generation vehicle automation systems. This new validation program points to the growing interest for adoption of Aeva's FMCW technology and is in addition to Aeva's other ongoing automotive opportunities including previously disclosed production RFQs with Global Top 10 Passenger OEMs.Aeva's unique FMCW technology is being incorporated into the OEM's vehicle automation projects in collaboration with a leading simulation and validation technology provider. For the validation program, vehicles equipped with Aeva 4D LiDAR(TM) sensors will gather precise data of the environment around the vehicle. The data will serve as the benchmark for validating its next-generation vehicle automation systems including sensing, perception, decision-making, and control systems.

07:10 EDT Gilat Satellite awarded approximately $4M contract for connectivity in LatAm - Gilat Satellite Networks announced that it has secured approximately $4 Million contract to provide rural connectivity including banking transactions in Latin America, LatAm, for a period of 3 years. Gilat provides critical connectivity for people living in remote areas who rely on the bank for payment services, as well as support services for senior citizens, families, and other underserved populations. "We are very pleased to support essential banking services in the rural areas of Latin America," stated Ron Levin, Gilat's Chief Commercial Officer. "Over the years, we have built a robust satellite network, continuously enhancing it with the latest technological advancements. This ensures that we consistently meet the high-quality standards required for business continuity, even in remote areas and in the face of potential disasters."

07:08 EDT KKR acquires operator of near-airport parking The Parking Spot, no terms - KKR has acquired The Parking Spot or TPS the nation's leading owner and operator of near-airport parking properties, from an affiliate of Green Courte Partners a private equity real estate investment firm. Financial terms of the transaction were not disclosed. "The Parking Spot has demonstrated a compelling track record of growth and delivery of a high-quality offering to travelers that aligns well with our investment philosophy," said Dash Lane, Partner at KKR. "With its strong and established platform, well-known industry brand, and superior customer service, TPS is recognized as an industry leader. Above all, we are strong believers in the TPS management team and their vision, along with the employees who have contributed meaningfully to the Company's success. We are eager to work with them to further build on their impressive performance and capitalize on the numerous growth opportunities that lie ahead."

07:08 EDT Avalo Therapeutics announces first patient dosed in Phase 2 LOTUS trial - Avalo Therapeutics announced that the first patient has been dosed in the Company's Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa. AVTX-009 is a humanized monoclonal antibody that binds to interleukin-1beta with high affinity and neutralizes its activity. The LOTUS Trial is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial with two AVTX-009 dose regimens to evaluate the efficacy and safety of AVTX-009 in approximately 180 adults with moderate to severe hidradenitis suppurativa. Subjects will be randomized to receive either one of two doses of AVTX-009 or placebo during a 16-week treatment phase. The primary efficacy endpoint is the proportion of subjects achieving Hidradenitis Suppurativa Clinical Response at Week 16. Secondary objectives include but are not limited to: proportion of patients achieving HiSCR50 and HiSCR90 as well as change from baseline in: International HS Severity Score System, draining fistula count, abscess and inflammatory nodule count and patients achieving at least a 30% reduction on a numerical rating scale in Patient's Global Assessment of Skin Pain. The number of patients with anti-drug antibodies, safety, and tolerability will be assessed.

07:06 EDT Teva biosimilar candidate is accepted for review by U.S. FDA, E.U. EMA - Teva Pharmaceutical Industries announced that the United States Food and Drug Administration, FDA, has accepted, and the European Medicines Agency, EMA, has validated, applications for TVB-009P, a biosimilar candidate to Prolia. Both applications, a Biologics License Application, BLA, in the U.S., seeking interchangeability, and a Marketing Authorization Application, MAA, in the European Union, EU, include all indications approved for the reference product, Prolia, including conditions with a high risk for fracture, such as osteoporosis in postmenopausal women. The FDA's anticipated decision and EMA's expected opinion are anticipated in the second half of 2025.

07:05 EDT Biglari Capital sends letter to Cracker Barrel shareholders, urges change - Biglari Capital issued the following letter to shareholders of Cracker Barrel Old Country Store. The letter stated, in part, "Dear Shareholders of Cracker Barrel Old Country Store Inc.: Through affiliated entities, we have been shareholders of Cracker Barrel since 2011. We currently own 2,069,141 shares. Since 2019, the shareholders of Cracker Barrel have collectively lost over $2.9 billion in market value. As 9.3% owners of the stock, we have lost our proportional share. Neither the appointment of Julie Felss Masino as the company's CEO nor her new transformation plan has restored shareholder confidence. In fact, Cracker Barrel's share price fell 14.5% when the transformation plan was revealed on May 16, 2024, and is down 50.9% since Ms. Masino became CEO-elect on August 7, 2023. This letter is devoted not only to the current plans of the company but also to the historical decisions that led to Cracker Barrel's current crisis. A postmortem is instructive so as not to repeat past mistakes." Reference Link

07:04 EDT Cleveland-Cliffs announces expiration of HSR Act waiting period for Stelco deal - Cleveland-Cliffs announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with its pending acquisition of Stelco Holdings. The expiration of the HSR Act waiting period clears an important regulatory hurdle and marks a significant step toward the closing of this acquisition, which is expected to occur in the fourth quarter of 2024 following the satisfaction or waiver of other customary closing conditions and approvals.

07:02 EDT GSK presents new data from AReSVi-006 phase III trial of Arexvy - GSK announced new data from the AReSVi-006, Adult Respiratory Syncytial Virus, phase III trial evaluating the efficacy of a single dose of Arexvy against lower respiratory tract disease, LRTD, caused by respiratory syncytial virus, RSV in adults aged 60 years and older, including those at increased risk over three full RSV seasons. These data will be presented today at the CHEST 2024 Annual Meeting, organized by the American College of Chest Physicians. Today's results indicate that after a single dose of GSK's RSV vaccine, cumulative efficacy over three full RSV seasons was clinically meaningful at 62.9% against RSV-LRTD and 67.4% against severe RSV-LRTD compared to placebo. In the third season, the vaccine's efficacy was 48.0% against RSV-LRTD. These results include efficacy against different RSV subtypes, in adults with advancing age, and those with certain underlying medical conditions. Since RSV can exacerbate medical conditions and potentially lead to hospitalisations, cumulative efficacy over three RSV seasons has the potential for significant health impact. It has the potential to offer health care professionals flexibility to administer the vaccine year-round. Over time, revaccination is expected to be required to maintain an optimal level of protection.

06:53 EDT Endeavour Silver reports Q3 2024 production results - Endeavour Silver reported Q3 2024 production of 874,717 silver ounces and 9,290 gold ounces, for silver equivalent production of 1.6 million ounces. Total year-to-date production of 6.0 million AgEq ounces is tracking towards the updated 2024 production guidance of 7.3 million to 7.6 million AgEq ounces. Production decreased in August and September due to a trunnion failure of the primary ball mill. At Guanacevi, production for Q3 2024 amounted to 768,905 silver ounces and 2,828 gold ounces. Estimated fabrication timing remains at 15 weeks with the mine being back to full operations in December 2024. With throughput remaining steady, gold production at Bolanitos continues to be slightly above plan due to higher gold grades. Silver production continues to be slightly below plan due to lower silver grades. Processed ore grades are expected to have similar variation for Q4. The company sold 1,017,392 silver ounces and 9,412 gold ounces during Q3. Drawdowns totaling $25M were made during Q3 2024 to develop the Terronera mine, and a further and final drawdown of $35M subsequent to quarter end.

06:49 EDT Merck's Keytruda met primary endpoint in Phase 3 carcinoma study - Merck announced that the Phase 3 KEYNOTE-689 trial evaluating Keytruda - pembrolizumab -, Merck's anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma - LA-HNSCC - met its primary endpoint of event-free survival. The study evaluated Keytruda as neoadjuvant therapy, then continued after surgery in combination with standard-of-care radiotherapy as adjuvant therapy, followed by Keytruda as maintenance therapy, vs. adjuvant radiotherapy alone. At a pre-specified first interim analysis conducted by an independent Data Monitoring Committee, there was a statistically significant and clinically meaningful improvement in EFS for patients receiving the Keytruda perioperative treatment regimen. The study also showed a statistically significant improvement in major pathological response, a key secondary endpoint, for patients in the Keytruda arm vs. adjuvant radiotherapy alone. The safety profile of Keytruda was consistent with that observed in previously reported studies; no new safety signals were identified. A trend toward improvement in overall survival, another key secondary endpoint, was observed for Keytruda as neoadjuvant treatment and Keytruda in combination with standard-of-care radiotherapy as treatment after surgery and maintenance therapy with Keytruda. The OS results did not reach statistical significance in patients whose tumors were PD-L1 Combined Positive Score greater than or equal to10 at the time of this first interim analysis. OS will be evaluated at the next interim analysis.

06:34 EDT Air Lease provides Q3 activity update - Air Lease (AL) announced an update on aircraft investments, sales, and significant financing activities occurring in the third quarter of 2024. As of September 30, 2024, ALC's fleet was comprised of 485 owned aircraft and 64 managed aircraft, with 287 new aircraft on order from Airbus (EADSY) and Boeing (BA) set to deliver through 2029. Aircraft Investments: Delivered 20 new aircraft from ALC's orderbook including three Airbus A220s, six Airbus A321neos, three Airbus A330-900neos, two Airbus A350-900s, two Boeing 737-8s, one Boeing 787-9, and three Boeing 787-10s. Aircraft investments in the quarter totaled approximately $1.9B. Sales: Sold nine aircraft to third-party buyers. Aircraft sales proceeds for the quarter totaled approximately $340M.

06:17 EDT Clover Health's Counterpart Health names David Tsay Chief Medical Officer - Counterpart Health appointed David Tsay as Chief Medical Officer. David Tsay has over two decades of experience in health technology, product development, and clinical innovation. Prior to Counterpart, Dr. Tsay served in clinical leadership roles in the technology industry, most recently as Chief Medical Officer at Cue Health where he led regulatory, clinical, and medical affairs. Before Cue Health, Dr. Tsay led the clinical team for digital health medical device products at Apple. Prior to Apple, Dr. Tsay served as Associate Chief Transformation Officer at New York-Presbyterian.

06:09 EDT Can-Fite BioPharma treatment of pancreatic cancer granted FDA orphan status - Can-Fite BioPharma's namodenoson was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post to the agency's website. Reference Link

06:06 EDT Honeywell to spin off Advanced Materials business into publicly traded company - Honeywell announced a plan to spin off its Advanced Materials business into an independent, U.S. publicly traded company, which is targeted to be completed by the end of 2025 or early 2026. Honeywell expects to execute the planned spin in a tax-free manner to its shareowners. The planned spin-off of the Advanced Materials business follows four recent acquisitions Honeywell announced as part of its capital deployment strategy. Honeywell is currently on pace to exceed its commitment to deploy at least $25B toward capital expenditures, dividends, share purchases and accretive acquisitions through 2025, with approximately $9B deployed towards acquisitions to date in 2024. Following the completion of the planned spin of the Advanced Materials business. Upon completion of the spin-off, the Advanced Materials business will be a sustainability-focused specialty chemicals and materials pure play with positions across fluorine products, electronic materials, industrial grade fibers, and healthcare packaging solutions. Advanced Materials is expected to have FY24 estimated revenue of between $3.7B and $3.9B with an EBITDA margin greater than 25%. The planned spin-off transaction is targeted for completion by the end of 2025 or early 2026, subject to certain customary conditions, including, among others, the filing and effectiveness of applicable filings with the U.S. Securities and Exchange Commission, assurance that the spin-off of the Advanced Materials business will be tax-free to Honeywell's shareowners, receipt of applicable regulatory approvals and final approval by Honeywell's board of directors. Approval by Honeywell's shareowners is not required. The spin transaction will not impact Honeywell's FY24 guidance. As the process progresses, Honeywell intends to provide additional information regarding the future management team and board of directors for the independent Advanced Materials company.

05:28 EDT Nuvei, JCB International expand international partnership in APAC - JCB International announced that it has expanded its global partnership with Nuvei to include Singapore and Hong Kong. This expansion builds upon Nuvei's existing relationship with JCB in Europe. Nuvei now offers JCB acceptance to its global merchant ecosystem, enabling JCB's community of more than 158M cardmembers to pay directly to online businesses integrated with Nuvei.

05:20 EDT EchoStar announces three-year supply agreement with Connected - EchoStar Mobile and Connected, a startup dedicated to delivering narrowband connectivity from space, have announced a strategic partnership to revolutionize off-grid connectivity. This collaboration introduces Connected One, an IoT solution that leverages EchoStar's satellite technology to bridge connectivity gaps in remote and underserved regions, even when venturing off the grid. Under the new three-year agreement, EchoStar Mobile will supply its advanced EM2050 modules to Connected. This integration enhances Connected's product portfolio by incorporating direct-to-device satellite communications, reducing the need for extensive ground infrastructure and increasing connectivity reliability in the most remote regions through EchoStar's geostationary satellite network.

05:10 EDT Baidu CFO Rong Luo to switch roles, Junjie He named interim CEO - Baidu announced certain management rotation. Rong Luo will be serving as executive VP in charge of the Baidu Mobile Ecosystem Group, or MEG, and no longer serve as CFO, effective immediately. Concurrently, Junjie He has been appointed as the interim CFO of the company, transitioning from his current position as senior VP and head of the Baidu Mobile Ecosystem Group, or MEG.